203 related articles for article (PubMed ID: 23799421)
1. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Takahashi H; Ohigashi H; Gotoh K; Marubashi S; Yamada T; Murata M; Ioka T; Uehara H; Yano M; Ishikawa O
Ann Surg; 2013 Dec; 258(6):1040-50. PubMed ID: 23799421
[TBL] [Abstract][Full Text] [Related]
2. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
4. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
5. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O
Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512
[TBL] [Abstract][Full Text] [Related]
6. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Takahashi H; Ohigashi H; Ishikawa O; Gotoh K; Yamada T; Nagata S; Tomita Y; Eguchi H; Doki Y; Yano M
Ann Surg; 2012 Jan; 255(1):95-102. PubMed ID: 22123160
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
11. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
[TBL] [Abstract][Full Text] [Related]
12. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Akita H; Wada H; Tomokuni A; Asukai K; Takahashi Y; Yanagimoto Y; Matsunaga T; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Yamamoto T; Nakanishi M; Shirayanagi M; Yamasaki T; Ohue M; Yano M; Sakon M; Ishikawa O
Surgery; 2018 Dec; 164(6):1168-1177. PubMed ID: 30146098
[TBL] [Abstract][Full Text] [Related]
13. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment.
Ushida Y; Inoue Y; Ito H; Oba A; Mise Y; Ono Y; Sato T; Saiura A; Takahashi Y
Pancreatology; 2021 Jan; 21(1):130-137. PubMed ID: 33303373
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Gemcitabine-based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer.
Ravikumar R; Fusai G
Ann Surg; 2015 Dec; 262(6):e103. PubMed ID: 24854654
[No Abstract] [Full Text] [Related]
15. Reply to Letter: "Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer".
Takahashi H; Ishikawa O
Ann Surg; 2015 Dec; 262(6):e103-4. PubMed ID: 24670859
[No Abstract] [Full Text] [Related]
16. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
18. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
[TBL] [Abstract][Full Text] [Related]
19. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Hirata T; Teshima T; Nishiyama K; Ogawa K; Otani K; Kawaguchi Y; Konishi K; Tomita Y; Takahashi H; Ohigashi H; Ishikawa O
Radiother Oncol; 2015 Jan; 114(1):122-7. PubMed ID: 25614389
[TBL] [Abstract][Full Text] [Related]
20. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Mataki Y; Shinchi H; Maemura K; Kurahara H; Kawasaki Y; Desaki R; Ueno S; Sakoda M; Iino S; Higashi M; Takao S; Natsugoe S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1637-40. PubMed ID: 24393873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
